Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Chronic Hand Dermatitis
Interventions
DRUG

Acitretin

All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.

Trial Locations (2)

N8W 5L7

Windsor Clinical Research Inc., Windsor

H2K 4L5

Innovaderm Research Inc., Montreal

Sponsors
All Listed Sponsors
collaborator

Tribute Pharmaceuticals

INDUSTRY

lead

Innovaderm Research Inc.

OTHER